HABP/VABP Trial—REPROVE

Clinical efficacy demonstrated vs meropenem in critically ill patients

HABP/VABP Phase 3 trial

STUDY DESIGN1

TYPE OF TRIAL

Phase 3, multinational, multicenter, double-blind, randomized, noninferiority trial

STUDY POPULATION

870 adults hospitalized with HABP/VABP; the ITT population included all randomized patients who received study drug. The micro-ITT population included all patients with at least one Gram-negative pathogen.

The median age was 66 years and 74.1% were male. The median APACHE II score was 14. The majority of patients were from China (33.1%) and Eastern Europe (25.5%). There were no patients enrolled within the United States. Overall 43.6% of patients were ventilated at enrollment, including 33.3% with VABP and 10.2% with ventilated HABP. Bacteremia at baseline was present in 4.8% of patients.

COMPARATIVE AGENTS

AVYCAZ 2.5 g (ceftazidime 2 grams and avibactam 0.5 grams) IV every 8 hours

Meropenem 1 gram intravenously every 8 hours

Study medication dosages were adjusted per renal function.

The protocol allowed for administration of prior and concomitant systemic antibacterial therapy.

TREATMENT DURATION

7 to 14 days

PRIMARY ENDPOINTS

The primary efficacy endpoint was 28-day all-cause mortality evaluated in the ITT population (28 to 32 days after randomization).

APACHE II, Acute Physiology and Chronic Health Evaluation II.

ITT, intent-to-treat.

IV, intravenous.

micro-ITT, microbiological intent-to-treat.

28-day all-cause mortality and clinical cure rates vs meropenem1

  • AVYCAZ was noninferior to meropenem with regard to the primary endpoint (28-day all-cause mortality in the ITT population)

28-DAY ALL-CAUSE MORTALITY RATES (ITT)

Bar Graph of 28-DAY ALL-CAUSE MORTALITY RATES (ITT) Representing AVYCAZ as 9.6% and Meropenem as 8.3%

28-DAY ALL-CAUSE MORTALITY RATES (micro-ITT)

chart showing REPROVE Phase 3 clinical trial cure rates at at the day 21-25 visit (mMITT)
  • The control group mortality rates were lower than that observed in other HABP/VABP trials which may impact generalizability of results. However, review of patient characteristics reflecting disease severity indicates the study enrolled a representative HABP/VABP population

CLINICAL CURE RATES VS MEROPENEM AT TOC (ITT)*

Bar Graph of Clinical Cure Rates at TOC (ITT) Representing AVYCAZ as 67.2% and Meropenem as 69.1%

*A quantitative estimate of treatment effect has not been established for the clinical cure endpoint.

Clinical cure was defined as resolution or significant improvement in signs and symptoms associated with pneumonia and cessation of antibacterial treatment for HABP/VABP.

The TOC visit occurred 21 to 25 days from randomization.

CI, confidence interval.

TOC, test of cure.

Clinical efficacy demonstrated in patients with bacteremia1

>10% of AVYCAZ patients in the micro-ITT population were bacteremic at baseline (21/187)

BACTEREMIA SUBSET POPULATION: SURVIVAL THROUGH THE DAY-28 FOLLOW-UP VISIT (micro-ITT)

Bar Graph of Bacteremia Subset Population: Survival Through the Day- 28 Follow-up Visit (micro-ITT): Representing AVYCAZ as 95.2% and Meropenem as 86.7%

BACTEREMIA SUBSET POPULATION: CLINICAL CURE RATES AT TOC (micro-ITT)

Bar graph of Bacteremia Subset Population: Clinical Cure Rates at TOC (micro-itt): Representing AVYCAZ as 61.9% and Meropenem as 60.0%
  • Of the 382 patients in the micro-ITT population, 36 patients were bacteremic at baseline

Clinical efficacy in patients who received potentially effective prior or concomitant antibacterial therapy1

The administration of prior or concomitant Gram-negative antibacterial therapy can confound the assessment of trial results. However, a subgroup analysis of 28-day all-cause mortality in subjects who received 24 hours or less of potentially effective antibacterial therapy prior to randomization and 72 hours or less of concomitant potentially effective antibacterial therapy following randomization produced results similar to the overall ITT population (AVYCAZ mortality 10.0% [20/200], meropenem 6.2% [12/195] [difference 3.8%; 95% CI: -1.6% to 9.5%]). In the subset of patients who received more than 24 hours of potentially effective antibacterial therapy prior to randomization or more than 72 hours of concomitant potentially effective antibacterial therapy following randomization, results were similar to the overall ITT population (AVYCAZ 9.7% [25/258], meropenem 10.5% [28/266] [difference -0.08%; 95% CI: -6.1% to 4.4%]).

Clinical efficacy vs ceftazidime-NS Gram-negative pathogens, including K. pneumoniae and P. aeruginosa1

  • At baseline, 28.3% (108/382) of patients in the micro-ITT population had Gram-negative isolates that were not susceptible to ceftazidime, including 53 patients with K. pneumoniae and 28 patients with P. aeruginosa isolates1
  • Among the inclusion criteria for the study was a need for mechanical ventilation or, for already ventilated patients, acute changes made in the ventilator support system to enhance oxygenation, as determined by, for example, arterial blood gas or worsening PaO2/FiO22
  • The micro-ITT population included a greater baseline proportion of patients who were ventilated (68.6%), had VABP (54.2%), had late VABP (40.3%), and were bacteremic (9.4%) than the ITT population2

CEFTAZIDIME-NS SUBSET POPULATION: 28-DAY ALL-CAUSE MORTALITY (micro-ITT)1

Bar graph of Ceftazidime ns subset population 28 day all cause morality micro itt Representing AVYCAZ as 8.2% and Meropenem as 8.5%

CEFTAZIDIME-NS SUBSET POPULATION: CLINICAL CURE RATES AT TOC (micro-ITT)1

Bar graph of Ceftazidime-nz Subset Population Clinical Cure Rates at TOC (micro-ITT): Representing Avycaz as 75.5% and Meropenem as 71.2%

NS, nonsusceptible.

IDSA treatment guidance for antimicrobial-resistant Gram-negative bacterial infections recommends AVYCAZ as a preferred antibiotic when facing the challenge of Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa).*3

This recommendation includes infections such as HABP/VABP.3

*DTR is defined as P. aeruginosa exhibiting nonsusceptibility to all of the following: piperacillin-tazobactam, ceftazidime, cefepime, aztreonam, meropenem, imipenem-cilastatin, ciprofloxacin, and levofloxacin.3
IDSA, Infectious Diseases Society of America.

Clinical efficacy vs a broad range of key Gram-negative pathogens in HABP/VABP1

28-DAY ALL-CAUSE MORTALITY BY BASELINE PATHOGEN (micro-ITT)

Chart depicting 28-Day All-Cause Mortality by Baseline Pathogen (micro-ITT) comparing AVYCAZ and Merpenem

CLINICAL CURE RATES AT TOC BY BASELINE PATHOGEN (micro-ITT)1

Chart depicting Clinical Cure Rates At toc by Baseline pathogen (micro-ITT) comparing AVYCAZ and Merpenem

HABP/VABP Pediatric Study

An open-label single-dose pharmacokinetic (PK) and safety trial was conducted in pediatric patients with HABP/VABP and enrolled four patients aged 11.6 months to 9.4 years.

INDICATIONS AND USAGE

Complicated Intra-Abdominal Infections (cIAI)

AVYCAZ® (ceftazidime and avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae, Klebsiella oxytoca, Citrobacter freundii complex, and Pseudomonas aeruginosa.

Complicated Urinary Tract Infections (cUTI), including Pyelonephritis

AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter freundii complex, Proteus mirabilis, and Pseudomonas aeruginosa.

Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)

AVYCAZ (ceftazidime and avibactam) is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in adult and pediatric patients (at least 31 weeks gestational age) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

AVYCAZ is contraindicated in patients with known serious hypersensitivity to the components of AVYCAZ (ceftazidime and avibactam), avibactam-containing products, or other members of the cephalosporin class.

WARNINGS AND PRECAUTIONS

  • In a Phase 3 cIAI trial in adult patients, clinical cure rates were lower in a subgroup of patients with baseline creatinine clearance (CrCl) of 30 to less than or equal to 50 mL/min compared to those with CrCl greater than 50 mL/min. The reduction in clinical cure rates was more marked in patients treated with AVYCAZ plus metronidazole compared to meropenem-treated patients. Within this subgroup, patients treated with AVYCAZ received a 33% lower daily dose than is currently recommended for patients with CrCl of 30 to less than or equal to 50 mL/min. Clinical cure rate in patients with normal renal function/mild renal impairment (CrCl greater than 50 mL/min) was 85% (322/379) with AVYCAZ plus metronidazole vs 86% (321/373) with meropenem, and clinical cure rate in patients with moderate renal impairment (CrCl 30 to less than or equal to 50 mL/min) was 45% (14/31) with AVYCAZ plus metronidazole vs 74% (26/35) with meropenem. The decreased clinical response was not observed for patients with moderate renal impairment at baseline (CrCl 30 to less than or equal to 50 mL/min) in the Phase 3 cUTI trials or the Phase 3 HABP/VABP trial. Monitor CrCl at least daily in adult and pediatric patients with changing renal function and adjust the dosage of AVYCAZ accordingly.
  • Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving beta-lactam antibacterial drugs. Before therapy with AVYCAZ is instituted, careful inquiry about previous hypersensitivity reactions to other cephalosporins, penicillins, or carbapenems should be made. Exercise caution if this product is to be given to a penicillin- or other beta-lactam-allergic patient because cross sensitivity among beta-lactam antibacterial drugs has been established. Discontinue the drug if an allergic reaction to AVYCAZ occurs.
  • Clostridioides difficile-associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial drugs, including AVYCAZ, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary because CDAD has been reported to occur more than 2 months after the administration of antibacterial drugs. If CDAD is suspected or confirmed, antibacterials not directed against C. difficile should be discontinued, if possible.
  • Seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported in patients treated with ceftazidime, particularly in the setting of renal impairment. Adjust dosing based on CrCl.
  • Prescribing AVYCAZ in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

ADVERSE REACTIONS

Adult cIAI, cUTI, and HABP/VABP Patients

The most common adverse reactions in adult patients with cIAI (≥5% when used with metronidazole) were diarrhea (8%), nausea (7%), and vomiting (5%). The most common adverse reactions in adult patients with cUTI (3%) were diarrhea and nausea. The most common adverse reactions in adult patients with HABP/VABP (≥5%) were diarrhea (15%) and vomiting (6%).

Pediatric Patients

The most common adverse reactions (>3%) in pediatric patients aged 3 months and older were vomiting, diarrhea, rash, and infusion site phlebitis.

The most common adverse reactions (>3%) in pediatric patients less than 3 months of age were vomiting and increased transaminases.